FAAH inhibitors in the limelight, but regrettably

Abstract. This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the availab...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallet, Christophe, Dubray, Claude, Dualé, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2016
Materias:
Guest Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941643/
https://www.ncbi.nlm.nih.gov/pubmed/27191771
http://dx.doi.org/10.5414/CP202687
_version_ 1782442326386278400
author Mallet, Christophe
Dubray, Claude
Dualé, Christian
author_facet Mallet, Christophe
Dubray, Claude
Dualé, Christian
author_sort Mallet, Christophe
collection PubMed
description Abstract. This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.
format Online
Article
Text
id pubmed-4941643
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-49416432016-07-25 FAAH inhibitors in the limelight, but regrettably Mallet, Christophe Dubray, Claude Dualé, Christian Int J Clin Pharmacol Ther Guest Editorial Abstract. This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events. Dustri-Verlag Dr. Karl Feistle 2016-07 2016-05-18 /pmc/articles/PMC4941643/ /pubmed/27191771 http://dx.doi.org/10.5414/CP202687 Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Guest Editorial
Mallet, Christophe
Dubray, Claude
Dualé, Christian
FAAH inhibitors in the limelight, but regrettably
title FAAH inhibitors in the limelight, but regrettably
title_full FAAH inhibitors in the limelight, but regrettably
title_fullStr FAAH inhibitors in the limelight, but regrettably
title_full_unstemmed FAAH inhibitors in the limelight, but regrettably
title_short FAAH inhibitors in the limelight, but regrettably
title_sort faah inhibitors in the limelight, but regrettably
topic Guest Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941643/
https://www.ncbi.nlm.nih.gov/pubmed/27191771
http://dx.doi.org/10.5414/CP202687
work_keys_str_mv AT malletchristophe faahinhibitorsinthelimelightbutregrettably
AT dubrayclaude faahinhibitorsinthelimelightbutregrettably
AT dualechristian faahinhibitorsinthelimelightbutregrettably

Ejemplares similares